Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)
Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –
Spero Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Spero Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $47.00M, down 3.3% year over year. For fiscal 2025 it was $66.80M, up 39.2% from the year before. The highest annual figure on record is $103.78M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.80M | +39.2% |
| FY2024 | Dec 31, 2024 | $47.98M | -53.8% |
| FY2023 | Dec 31, 2023 | $103.78M | +94.0% |
| FY2022 | Dec 31, 2022 | $53.51M | +193.1% |
| FY2021 | Dec 31, 2021 | $18.26M | +95.7% |
| FY2020 | Dec 31, 2020 | $9.33M | -48.6% |
| FY2019 | Dec 31, 2019 | $18.15M | +357.6% |
| FY2018 | Dec 31, 2018 | $3.97M | +100.4% |
| FY2017 | Dec 31, 2017 | $1.98M | +490.7% |
| FY2016 | Dec 31, 2016 | $335.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $258.00K | -95.6% |
| Q4 FY2025 | Dec 31, 2025 | $41.30M | +174.5% |
| Q3 FY2025 | Sep 30, 2025 | $5.44M | -59.6% |
| Q2 FY2025 | Jun 30, 2025 | $14.19M | +39.1% |
| Q1 FY2025 | Mar 31, 2025 | $5.87M | -36.6% |
| Q4 FY2024 | Dec 31, 2024 | $15.04M | -79.5% |
| Q3 FY2024 | Sep 30, 2024 | $13.47M | -47.1% |
| Q2 FY2024 | Jun 30, 2024 | $10.20M | +275.4% |
| Q1 FY2024 | Mar 31, 2024 | $9.27M | +347.9% |
| Q4 FY2023 | Dec 31, 2023 | $73.52M | +55.0% |
| Q3 FY2023 | Sep 30, 2023 | $25.47M | +1169.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.72M | +36.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.07M | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $47.44M | +1628.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.01M | -34.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.99M | -61.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.07M | -71.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.74M | +43.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.06M | -23.3% |
| Q2 FY2021 | Jun 30, 2021 | $5.15M | +198.1% |
| Q1 FY2021 | Mar 31, 2021 | $7.30M | +329.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.91M | +174.0% |
| Q3 FY2020 | Sep 30, 2020 | $4.00M | -14.0% |
| Q2 FY2020 | Jun 30, 2020 | $1.73M | -19.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.70M | -78.0% |
| Q4 FY2019 | Dec 31, 2019 | $696.00K | -58.9% |
| Q3 FY2019 | Sep 30, 2019 | $4.64M | +605.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.16M | +365.7% |
| Q1 FY2019 | Mar 31, 2019 | $7.72M | +569.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.69M | +70.4% |
| Q3 FY2018 | Sep 30, 2018 | $658.00K | +10.2% |
| Q2 FY2018 | Jun 30, 2018 | $463.00K | +85.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.15M | +723.6% |
| Q4 FY2017 | Dec 31, 2017 | $993.00K | – |
| Q3 FY2017 | Sep 30, 2017 | $597.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $249.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $140.00K | – |
See a number that looks wrong?